期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Viral Hepatitis B under Tenofovir in Ouagadougou (Burkina Faso)
1
作者 Soudré Sandrine Marie-Odile Bobilwindé Napon Fahosiata +9 位作者 Zoungrana Steve Léonce Ouattara Zanga Damien Koura Mali guingané nanelin alice Somda Sosthène Coulibaly Aboubacar Beni Da Nathalie Salou Rodrigue Bougouma Alain Sombié Arsène Roger 《Open Journal of Gastroenterology》 2021年第8期141-150,共10页
<strong>Introduction</strong><span><span><span style="font-family:;" "=""><strong>:</strong> The treatment of viral hepatitis B is based on nucleotide... <strong>Introduction</strong><span><span><span style="font-family:;" "=""><strong>:</strong> The treatment of viral hepatitis B is based on nucleotide analogs(s). In Burkina Faso, tenofovir is the most widely used because of its effectiveness and cost. The aim of this study was to describe viral hepatitis B under tenofovir in Ouagadougou. <b>Material and Method</b>: This was a longitudinal study, carried out in the outpatient department of the University Hospital of Tengandogo from May 1, 2013 to September 31, 2020, <i>i.e.</i> a period of seven (07) years and five (05) months. All patients with chronic hepatitis B virus who had been taking tenofovir for at least one year were included in the study. Cases of hepatocellular carcinoma and co-infections with hepatitis D, C and human immunodeficiency viruses were excluded from the study. <b>Results</b>: Of 321 patients with hepatitis B, 120 were on tenofovir and 34 were included in our study. These were 24 men and 10 women with an average age of 39 years. Hepatitis B was most often discovered following systematic or voluntary screening (44.1%) or pain in the right hypochondrium (23.5%). The mean initial viral load was 7.9</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span><span><span style="font-family:;" "="">log. Ten patients had moderate compliance and four were non-compliant. No side effects were reported in 91.3% of cases. The virologic response was complete in 72.7% of patients after six months. Nine out of ten patients showed a biochemical response after 16 months. A histological response was observed in 19/27 patients within a mean of 26.7 months. HBs seroconversion was found in 2/24 patients. <b>Conclusion</b>: Tenofovir is effective in the treatment of viral hepatitis B, but HBs seroconversion is rarely achieved.</span></span></span> 展开更多
关键词 Viral Hepatitis B TENOFOVIR COMPLIANCE TOLERANCE EFFICACY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部